Showing results (411-420 of 428) with videos related to
Sort By:
Pageof 43
Molecular Oncology|April 28, 2009
Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530Tim P Green, Mike Fennell, Robin Whittaker, et al.Plos One|March 24, 2016
Agricultural Management and Climatic Change Are the Major Drivers of Biodiversity Change in the UKFiona Burns, Mark A Eaton, Kate E Barlow, et al.Proceedings of the National Academy of Sciences of the United States of America|July 4, 2020
Extensive sequence and structural evolution of Arginase 2 inhibitory antibodies enabled by an unbiased approach to affinity maturationDenice T Y Chan, Lesley Jenkinson, Stuart W Haynes, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2007
AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosisRobert W Wilkinson, Rajesh Odedra, Simon P Heaton, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 11, 2017
A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 AgonistRebecca Leyland, Amanda Watkins, Kathy A Mulgrew, et al.Journal for Immunotherapy of Cancer|April 17, 2025
LILRB2 blockade facilitates macrophage repolarization and enhances T cell-mediated antitumor immunityDes C Jones, Lorraine Irving, Rebecca Dudley, et al.Science Advances|October 18, 2023
CD73 controls Myosin II-driven invasion, metastasis, and immunosuppression in amoeboid pancreatic cancer cellsRemi Samain, Oscar Maiques, Joanne Monger, et al.Journal of Medicinal Chemistry|February 3, 2006
Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitorsFrédéric H Jung, Georges Pasquet, Christine Lambert-van der Brempt, et al.Nature|January 11, 2019
SETD3 is an actin histidine methyltransferase that prevents primary dystociaAlex W Wilkinson, Jonathan Diep, Shaobo Dai, et al.Oncotarget|September 15, 2016
Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapyGeoffrey S Williams, Bina Mistry, Sandrine Guillard, et al.Pageof 43